Suboptimal Responses in Chronic Myeloid Leukemia

The high response rates and increased survival associated with imatinib therapy prompted a paradigm shift in the management of chronic myeloid leukemia. However, 25% to 30% of imatinib-treated patients develop drug resistance or intolerance, increasing the risk of disease progression and poor progno...

Descripción completa

Detalles Bibliográficos
Autores principales: Jabbour, Elias, Saglio, Giuseppe, Hughes, Timothy P, Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412948/
https://www.ncbi.nlm.nih.gov/pubmed/22038681
http://dx.doi.org/10.1002/cncr.26391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412948/
https://www.ncbi.nlm.nih.gov/pubmed/22038681
http://dx.doi.org/10.1002/cncr.26391

Ejemplares similares